BioInvent: Results Strengthening in CTCL - Redeye
Bildkälla: Stockfoto

BioInvent: Results Strengthening in CTCL - Redeye

Redeye is increasingly optimistic about BI-1808. In the latest readout presented at ASH, 6 out of 13 patients with CTCL presented a response.

Redeye is increasingly optimistic about BI-1808. In the latest readout presented at ASH, 6 out of 13 patients with CTCL presented a response.
Börsvärldens nyhetsbrev